Zoonosis Emergentes y Re emergentes



Perspectives on Emerging Zoonotic Disease Research and Capacity Building in Canada.

Craig Stephen, Harvey Artsob, William R Bowie, Michael Drebot, Erin Fraser, Ted Leighton, Muhammad Morshed, Corinne Ong, and David Patrick. Canadian Journal of Infectious Diseases and Medical Microbiology. Issue 6, Volume 15 (2004).


Powassan Virus: An Emerging Arbovirus of Public Health Concern in North America.

Vector-Borne and Zoonotic DiseasesVol. 17, No. 7 Review. Free Access. Hermance Meghan E.  and Thangamani Saravanan. Published Online:1 Jul 2017



Powassan Virus Disease in the United States, 2006–2016.

Vector-Borne and Zoonotic Diseases. Original Article. Krow-Lucal Elisabeth R., Lindsey Nicole P., Fischer Marc, and Hills Susan L. Published Online:13 Mar 2018



Molecular and Epidemiologic Analysis of Reemergent Salmonella enterica Serovar Napoli, Italy, 2011–2015.

Sabbatucci M, Dionisi A, Pezzotti P, et al. Emerging Infectious Diseases. 2018;24(3):562-565. doi:10.3201/eid2403.171178.


Prioritizing Zoonoses for Global Health Capacity Building—Themes from One Health Zoonotic Disease Workshops in 7 Countries, 2014–2016.

Salyer SJ, Silver R, Simone K, et al.  Emerging Infectious Diseases. 2017;23(13).



Cambio climático: efecto sobre la reemergencia de enfermedades infecciosas y parasitarias.

Díaz S. P: Revista electrónica de Veterinaria: 2017 Volumen 18 Nº 9 -



High Rate of MCR-1–Producing Escherichia coli and Klebsiella pneumoniae among Pigs, Portugal.

Kieffer N, Aires-de-Sousa M, Nordmann P, et al. Emerging Infectious Diseases. 2017;23(12):2023-2029. doi:10.3201/eid2312.170883.


Outbreak of Yellow Fever among Nonhuman Primates, Espirito Santo, Brazil, 2017.

Fernandes N, Cunha M, Guerra J, et al. Emerging Infectious Diseases. 2017;23(12):2038-2041. doi:10.3201/eid2312.170685.


Avian Influenza A(H7N2) Virus in Human Exposed to Sick Cats, New York, USA, 2016.

Marinova-Petkova A, Laplante J, Jang Y, et al.  Emerging Infectious Diseases. 2017;23(12):2046-2049. doi:10.3201/eid2312.170798.


Fish-borne nematodiases in South America: neglected emerging diseases.

J.C. Eiras (a1), G.C. Pavanelli (a2), R.M. Takemoto (a3) and Y. Nawa (a4):


Published online: 25 October 2017.


Emerging and re-emerging infectious diseases in Iran.

Najmeh Parhizgari, Mohammad Mehdi Gouya, Ehsan Mostafavi. Iranian Journal of Microbiology 2017. 9(3):122-142.


Fatal Rocky Mountain Spotted Fever along the United States–Mexico Border, 2013–2016.    

Drexler NA, Yaglom H, Casal M, et al. Emerging Infectious Diseases. 2017;23(10):1621-1626. doi:10.3201/eid2310.170309.


Effect of Intermediate Hosts on Emerging Zoonoses.

Jing-an Cui, Fangyuan Chen, Shengjie Fan. Vector-Borne and Zoonotic Diseases. Aug 2017: 599-609.


Zoonosis y Parasitosis Emergentes.

Disponible en:



Powassan Virus: An Emerging Arbovirus of Public Health Concern in North America:

Hermance Meghan E. and Thangamani Saravanan. Vector-Borne and Zoonotic Diseases. May 2017.



Surveillance of zoonotic infectious diseases transmitted by small companion animals. Emerg Infect Dis [Internet].

Day MJ, Breitschwerdt E, Cleaveland S, Karkare U, Khanna C, Kirpensteijn J, et al.2012 Dec [date cited].



An Ebola vaccine: first results and promising opportunities


AM Henao-Restrepo, IM Longini, M Egger, et al. Efficacy and effectiveness of
an rVSV-vectored vaccine expressing Ebola surface
glycoprotein: interim results from the Guinea ring vaccination
cluster-randomised trial. The Lancet. Published Online 31 Jul 2015

Background. A recombinant, replication-competent vesicular stomatitis
virus-based vaccine expressing a surface glycoprotein of Zaire Ebolavirus
(rVSV-ZEBOV) is a promising Ebola vaccine candidate. We report the results
of an interim analysis of a trial of rVSV-ZEBOV in Guinea, West Africa.

Methods. For this open-label, cluster-randomised ring vaccination trial,
suspected cases of Ebola virus disease in Basse-Guinea (Guinea, West Africa)
were independently ascertained by Ebola response teams as part of a national
surveillance system. After laboratory confirmation of a new case, clusters
of all contacts and contacts of contacts were defined and randomly allocated
1:1 to immediate vaccination or delayed
(21 days later) vaccination with rVSV-ZEBOV (one dose of 2 x 10^7
plaque-forming units, administered intramuscularly in the deltoid muscle).
Adults (age greater than 18 years) who were not pregnant or breastfeeding
were eligible for vaccination. Block randomisation was used, with randomly
varying blocks, stratified by location (urban vs
rural) and size of rings (greater than 20 vs less than 20 individuals). The
study is open label and masking of participants and field teams to the time
of vaccination is not possible, but Ebola response teams and laboratory
workers were unaware of allocation to immediate or delayed vaccination.
Taking into account the incubation period of the virus of about 10 days, the
prespecified primary outcome was laboratory-confirmed Ebola virus disease
with onset of symptoms at least 10 days after randomisation. The primary
analysis was per protocol and compared the incidence of Ebola virus disease
in eligible and vaccinated individuals in immediate vaccination clusters
with the incidence in eligible individuals in delayed vaccination clusters.
This trial is registered with the Pan African Clinical Trials Registry,
number PACTR201503001057193.

Findings. Between 1 Apr 2015 and 20 Jul 2015, 90 clusters, with a total
population of 7651 people, were included in the planned interim analysis. 48
of these clusters (4123 people) were randomly assigned to immediate
vaccination with rVSV-ZEBOV, and 42 clusters (3528 people) were randomly
assigned to delayed vaccination with rVSV-ZEBOV.

In the immediate vaccination group, there were no cases of Ebola virus
disease with symptom onset at least 10 days after randomisation, whereas in
the delayed vaccination group there were 16 cases of Ebola virus disease
from 7 clusters, showing a vaccine efficacy of 100 percent (95 percent CI
74.7-100.0; p=0.0036). No new cases of Ebola virus disease were diagnosed in
vaccinees from the immediate or delayed groups from 6 days post-vaccination.
At the cluster level, with the inclusion of all eligible adults, vaccine
effectiveness was 75.1 percent (95 percent CI -7.1 to 94.2; p=0.1791), and 76.3 percent (95 percent CI -15.5 to 95.1; p=0.3351) with the inclusion of everyone
(eligible or not eligible for vaccination). 43 serious adverse events were
reported; 1 serious adverse event was judged to be causally related to
vaccination (a febrile episode in a vaccinated participant, which resolved
without sequelae). Assessment of serious adverse events is ongoing.

Interpretation. The results of this interim analysis indicate that
rVSV-ZEBOV might be highly efficacious and safe in preventing Ebola virus
disease, and is most likely effective at the population level when delivered
during an Ebola virus disease outbreak via a ring vaccination strategy.

Funding. WHO, with support from the Wellcome Trust (UK); Medecins Sans
Frontieres; the Norwegian Ministry of Foreign Affairs through the Research
Council of Norway; and the Canadian Government through the Public Health
Agency of Canada, Canadian Institutes of Health Research, International
Development Research Centre, and Department of Foreign Affairs, Trade and





National Center for Emerging and Zoonotic Infectious Diseases Accomplisments 2013


WHO: Ebola Response Roadmap Situation Report


Lessons to be learned from the ebolavirus outbreak in
West Africa


Declaración pública por jaurías de perros asilvestrados en Chile




Importance of animal/human health interface in potential Public Health Emergencies of International Concern in the Americas


The Control of Neglected Zoonotic Diseases




WHO | Rabies

Zoonoses. ... 
www.who.int/zoonoses/diseases/rabies/en/ - 25k


TDR | Research Priorities for Zoonoses and Marginalized ...

... Research Priorities for Zoonoses and Marginalized Infections. Share. Email
Twitter Facebook Google Delicious LinkedIn More... Print. ... 
www.who.int/entity/tdr/publications/zoonoses/en/ - 23k


WHO | Emerging zoonoses

Zoonoses. ... Emerging zoonoses. Contrary to "lingering" zoonoses, public
awareness of "emerging" zoonoses is very high. ... 
www.who.int/zoonoses/emerging_zoonoses/en/ - 22k


Zoonosis emergence linked to agricultural intensification and environmental change




Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus.
Rongbao Gao, M.D, et al.n engl j med 368;20 nejm.org may 16, 2013


Global Concerns Regarding Novel Influenza A (H7N9) Virus Infections
Timothy M. Uyeki, M.D., M.P.H., M.P.P., and Nancy J. Cox, Ph.D. n engl j med 368;20 nejm.org may 16, 2013


Avian influenza, human (75): WHO risk assess. disease profile




CDC releases final West Nile virus national surveillance data for 2012




Manual de procedimientos para la prevención, control y erradicación de la Influenza Aviar de alta patogenicidad
( I A A P )